Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chronic Non-bacterial Osteomyelitis: A Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Preserved postprandial suppression of bone turnover markers, despite increased fasting levels, in postmenopausal women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Effects of carbamazepine, eslicarbazepine, valproic acid and levetiracetam on bone microarchitecture in rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Nicola Napoli
  • Bente L Langdahl
  • Östen Ljunggren
  • Eric Lespessailles
  • George Kapetanos
  • Tomaz Kocjan
  • Tatjana Nikolic
  • Pia Eiken
  • Helmut Petto
  • Thomas Moll
  • Erik Lindh
  • Fernando Marin
Vis graf over relationer

This study aimed to describe clinical outcomes in patients prescribed teriparatide and followed up for 18 months after stopping the drug in real-life conditions. The Extended Forsteo® Observational Study analysed incident clinical fractures in 6-month intervals using logistic regression with repeated measures. Changes in back pain (visual analogue scale) and health-related quality of life (HRQoL; EQ-5D questionnaire) were analysed using mixed models for repeated measures. Patients were analysed if they had a post-baseline visit, regardless of whether and for how long they took teriparatide. Of 1531 patients analysed (90.7% female, mean age: 70.3 years), 76 (5.0%) never took teriparatide. Median treatment duration was 23.6 months. The adjusted odds of clinical fracture decreased by 47% in the > 12- to 18-month treatment period (p = 0.013) compared with the first 6-month period, with no statistically significant reduction in the > 18- to 24-month interval. The clinical fracture rate remained stable during the 18 months' post-teriparatide, when approximately 98% of patients took osteoporosis medication (51% bisphosphonates). Clinical vertebral fractures were reduced at every time period compared with the first 6 months. Adjusted mean back pain scores decreased and EQ-5D scores increased significantly at each post-baseline observation. In a real-life clinical setting, the risk of clinical fractures declined during 24 months of teriparatide treatment. This reduction was maintained 18 months after stopping teriparatide. In parallel, patients reported significant improvements in back pain and HRQoL. The results should be interpreted in the context of the non-controlled design of this observational study.

TidsskriftCalcified Tissue International
Udgave nummer4
Sider (fra-til)359-371
StatusUdgivet - 2018

ID: 54747697